ArticleIn vivo (Athens, Greece)
Molecular Hydrogen Capsule Therapy for Primary Biliary Cholangitis With Elevated IgG4: A Case Report on Immune Marker Normalization.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular hydrogen-rhodiola as an adjuvant therapy for ischemic stroke in internal carotid artery occlusion: A case report.Open medicine (Warsaw, Poland) · 2025Article
- Unmasking a B-Cell Linkage Phenotype in Severe Acute Meningoencephalitis: A Case Report of IVIG and HydroBox-assisted Immunomodulatory Therapy.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimPrimary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by bile duct destruction, cholestasis, and inflammation, often leading to fibrosis and cirrhosis. While ursodeoxycholic acid (UDCA) is the standard treatment, some patients exhibit suboptimal responses, necessitating adjunctive therapies. Molecular hydrogen (H CASE REPORT: A 44-year-old male with PBC, splenomegaly, and elevated IgG4 levels presented with acute cholestatic hepatitis. Laboratory tests revealed significantly elevated aspartate transaminase (AST) (279 U/l) and alanine aminotransferase (ALT) (183 U/l). Despite UDCA therapy, liver enzymes remained persistently high. On August 30, 2024, molecular hydrogen capsule therapy was introduced as adjunctive treatment. Over four months, AST and ALT levels declined to 95 U/l and 70 U/l, respectively, without adverse effects. Immune markers (KLRG-1, PD-1, and Tim3), previously reduced during PBC flares, normalized post-treatment. Imaging confirmed stable fibrosis, and IgG4 levels decreased, suggesting reduced autoimmune activity. The patient also reported improvements in fatigue and pruritus, enhancing overall quality of life.
conclusionMolecular hydrogen capsules therapy may serve as a safe and effective adjunctive treatment for PBC, contributing to improved liver enzyme levels, immune regulation, and patient well-being. Further studies are warranted to validate these findings and establish standardized treatment protocols in autoimmune liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.